

New Therapeutic Strategy for Regenerating Periodontal Tissue Based on the Combination of Amelogenin and Reapplications of Existing Grp78 Inducer

Takao Fukuda^{1*}, Terukazu Sanui^{1*}, Kyosuke Toyoda¹, Urara Tanaka¹, Kensuke Yamamichi¹, Takaharu Taketomi², and Fusanori Nishimura¹

¹Department of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan

²Dental and Oral Medical Center, Kurume University School of Medicine, Kurume, Japan

*Corresponding authors: Takao Fukuda, Department of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan

Terukazu Sanui, Department of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan, Tel: 81926426358; E-mail: tfukuda@dent.kyushu-u.ac.jp

Terukazu Sanui and Takao Fukuda contributed equally to this work

Received date: May 23, 2016; Accepted date: June 06, 2016; Published date: June 09, 2016

Copyright: © 2016 Fukuda T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The present study aims to develop a highly safe regenerative therapy that effectively induces periodontal tissue regeneration by targeting amelogenin and its newly associated molecule, glucose-regulated protein 78 (Grp78). The enamel matrix derivative (Emdogain® Gel, Straumann) is currently the only bioregeneration tool in use that is approved by the Japanese Ministry of Health, Labour and Welfare. However, in addition to the safety issues that exist owing to it being a foreign protein, a unified opinion on its mechanism of action at the signal transduction level remains unclear. Previously, our laboratory was the first to report the identification of a new amelogenin-associated molecule, Grp78, in osteoblasts. This association was later shown to promote the migration of periodontal ligament stem cells (PDLSCs), which play critical role in periodontal regeneration. Based on these results, we aim to establish the molecular basis for periodontal tissue regeneration via the combined use of recombinant amelogenin and inducers of Grp78 which could be applied by reapplication of existing drugs (drug repositioning).

Keywords: Enamel matrix derivative (EMD); Amelogenin; Glucose-regulated protein 78 (Grp78)

Introduction

Many of the recent periodontal treatments have focused on tissue regeneration, and some are producing positive results. Of these, an enamel substrate protein extracted from porcine fetal teeth germ, called enamel matrix derivative (EMD), is frequently used in periodontal regeneration surgery [1]. EMD has already been commercialized (known commercially as Emdogain® Gel), and is currently the only substance that uses biologically active proteins for the regeneration of periodontal tissue to have been approved by the Japanese Ministry of Health, Labour and Welfare. However, despite much effort to elucidate the molecular mechanism of EMD action, no unified opinion has been reached regarding its effects on the regeneration of periodontal tissue [1], its inhibition of downgrowth of the gingival epithelium [2], or its anti-inflammatory action [3]. Additionally, since the product is a foreign protein derived from porcine tooth germ, some health issues such as the possibility of allergic reactions and contamination with unknown viruses cannot be completely excluded, although no harmful effects have been reported [4].

The major (>95%) component of EMD, amelogenin, is an extracellular matrix (ECM) protein that is central to the regeneration of periodontal tissue [5]. The application of ECM proteins in regenerative medicine is not novel, with these proteins being implemented in wound recovery and other regenerative treatments in the medical field. For instance, amelogenin (Xelma®, Molnlycke Health Care, Gothenburg, Sweden) is also used in the treatment of hard to

heal ulcers [6]. The application of amelogenin to periodontal tissue regeneration is based on an attempt to mimic the tooth developmental environment [7]. Amelogenin is secreted by ameloblasts during germ tooth formation and, through its deposition into the dentin, it participates in the formation of periodontal tissues such as the cementum [8]. In the oral cavity of amelogenin knockout (KO) mice, the cementum is malformed and the osteoclasts exhibit abnormal differentiation [9]. Moreover, administration of recombinant amelogenin alone has been reported to induce periodontal regeneration in experimental animals [10]. To date, amelogenin-associated molecules such as LAMP-1, Noggin, cytokeratin, and N-acetylglucosamine have been reported, however these molecules target ameloblasts during the formation of enamel [11]. Presently, there is little progress in research into the molecular interactions between amelogenin and the cell group that migrates during periodontal tissue regeneration and coordinates osteoinduction related to repair. Therefore, identification of amelogenin-binding molecules in cells, such as osteoblasts and mesenchymal stem cell (MSC)-derived PDL stem cells (PDLSCs), which are important in the regeneration of periodontal tissue, was an indispensable topic of study. By conducting a proteome analysis focused on amelogenin, the applicants were able to succeed, for the first time worldwide, in identifying a new amelogenin-binding proteins in osteoblasts that includes Grp78 [12]. Furthermore, we also found that the interaction between amelogenin and Grp78 not only enhances cell proliferation in osteoblasts [12] but also contribute to cell migration in PDLSCs [13].

Grp78 is a member of heat shock protein (HSP) family that both participates in the cell defense [14] and controls Ca²⁺ homeostasis [15], which is important for hard tissue formation. While it is mainly located in the endoplasmic reticulum (ER), it also translocate to the

cell surface via its transmembrane domain [16]. Several studies of Grp78 are particularly relevant to the known actions of amelogenin, such as those shown below:

(1) Grp78 participation in osteoblast differentiation as a DMP-1-specific receptor [17]

(2) Cell surface expression of Grp78 influences cell proliferation [18], migration [19] and stem cell behavior [20]

(3) Grp78 promotes resolution of inflammation by inducing regulatory T cell [21,22]

These studies suggest the possibility that Grp78 exerts an influence on the cell-specific actions of Emdogain® Gel, namely, cellular adhesion, control of mesenchymal stem cell differentiation, suppression of epithelial cell proliferation, and anti-inflammatory action. Indeed, we have found that Grp78 participates in the promotion of osteoblast proliferation [12] and periodontal ligament stem cell migration [13] via an amelogenin stimulus. Grp78 is reported to have two anti-inflammatory pathways. First, Grp78 induces IL-10 secretion and attenuates TNF- α production in monocytes [21]. Second, while macrophages have also been known to play central roles in tissue regeneration, Grp78 stimulates monocytes change deactivated macrophage like phenotype to induce cytotoxic T lymphocyte antigen-4 (CTLA-4)⁺ regulatory T cell [22]. Considering these findings, induction of Grp78 could have advantages for the treatment of periodontal disease by inducing periodontal tissue regeneration and resolution of inflammation.

In recent years, it has become clear that heat shock proteins (HSP) including Grp78 participate in tissue regeneration, and progress is being made in their use in retinal detachment [23] and myocardial protection [24]. Heat shock protein inducers are frequently used clinically as anti-gastric ulcer drugs (e.g. Teprenone) [25], and since its safety has been confirmed, they are expected to find a practical use in drug repositioning. Furthermore, previous study has shown that the level of histone H3 lysine 9 methylation (H3K9me), the heterochromatin marker, is decreased at the promoter of Grp78 in the ethanol-treated mice. As the expression level of histone H3K9 methyltransferase EHMT2 (G9a) is also selectively decreased [26], it is very likely the histone methyltransferases G9a plays a role in the expression of Grp78 in mammals. As G9a/GLP complex has also been shown to interact with DNA methyltransferases [27] and plays a role in the maintenance of DNA methylation at imprinted loci [28], the expression of Grp78 might be controlled by two different epigenetic mechanisms: one is associated with heterochromatic histone modification H3K9me and the other is DNA methylation. Therefore, by inhibition of G9a and its partner protein GLP clinically, it might also facilitate the regenerating of periodontal tissue as expression level of Grp78 might be increased.

Recent efforts in the treatment of periodontal disease have focused on cell-based endogenous regenerative technology by recruitment of stem cell-based therapeutics [29,30]. Due to their multipotency and paracrine effect, stem cells appear to have a promising therapeutic potential in regenerative medicine, thereby providing a cellular source for the regeneration of the different missing periodontal tissues. Although remarkable results have been produced by regenerative treatments using cell transplants, especially using stem cells, issues with their clinical application, such as the required facilities and costs, are currently imposing many hurdles. In contrast, the application of the clinically effective Emdogain® Gel and Teprenone will likely lead to

the development of safe, molecularly targeted, regenerative treatments that target amelogenin, Grp78, and perhaps other HSPs.

Acknowledgments

This work was supported by Grants-in-Aid for Scientific Research C (26463137) and Research Activity Start-up (15H06492) from the Japan Society for the Promotion of Science.

Author Disclosure Statement

The authors have declared that no conflicts of interest exist.

References

1. Sculean A, Kiss A, Miliauskaitė A, Schwarz F, Arweiler NB, et al. (2008) Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. *J Clin Periodontol* 35: 817-824.
2. Kawase T, Okuda K, Yoshie H, Burns DM (2000) Cytostatic action of enamel matrix derivative (EMDOGAIN) on human oral squamous cell carcinoma-derived SCC25 epithelial cells. *J Periodontol Res* 35: 291-300.
3. Miron RJ, Dard M, Weinreb M (2015) Enamel matrix derivative, inflammation and soft tissue wound healing. *J Periodontol Res* 50: 555-569.
4. Miron RJ, Sculean A, Cochran DL, Froum S, Zucchelli G, et al. (2016) 20 years of Enamel Matrix Derivative: The past, the present and the future. *J Clin Periodontol*.
5. Chen E, Piddington R, Decker S, Park J, Yuan ZA, et al. (1994) Regulation of amelogenin gene expression during tooth development. *Dev Dyn* 199: 189-198.
6. Romanelli M, Dini V, Vowden P, Agren MS (2008) Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: experimental and clinical evidence. *Clin Interv Aging* 3: 263-272.
7. Gestrelius S, Lyngstadaas SP, Hammarström L (2000) Emdogain--periodontal regeneration based on biomimicry. *Clin Oral Investig* 4: 120-125.
8. Bosshardt DD, Nanci A (2004) Hertwig's epithelial root sheath, enamel matrix proteins, and initiation of cementogenesis in porcine teeth. *J Clin Periodontol* 31: 184-192.
9. Hatakeyama J, Sreenath T, Hatakeyama Y, Thyagarajan T, Shum L, et al. (2003) The receptor activator of nuclear factor- κ B ligand-mediated osteoclastogenic pathway is elevated in amelogenin-null mice. *J Biol Chem* 278: 35743-35748.
10. Haze A, Taylor AL, Haegewald S, Leiser Y, Shay B, et al. (2009) Regeneration of bone and periodontal ligament induced by recombinant amelogenin after periodontitis. *J Cell Mol Med* 13: 1110-1124.
11. Wang H, Tannukit S, Zhu D, Snead ML, Paine ML (2005) Enamel matrix protein interactions. *J Bone Miner Res* 20: 1032-1040.
12. Fukuda T, Sanui T, Toyoda K, Tanaka U, Taketomi T, et al. (2013) Identification of novel amelogenin-binding proteins by proteomics analysis. *PLoS One* 8: e78129.
13. Toyoda K, Fukuda T, Sanui T, Tanaka U, Yamamichi K, et al. (2016) Grp78 Is Critical for Amelogenin-Induced Cell Migration in a Multipotent Clonal Human Periodontal Ligament Cell Line. *J Cell Physiol* 231: 414-27.
14. Rutherford SL (2003) Between genotype and phenotype: protein chaperones and evolvability. *Nat Rev Genet* 4: 263-274.
15. Clapham DE (2007) Calcium signaling. *Cell* 131: 1047-1058.
16. Zhang Y, Liu R, Ni M, Gill P, Lee AS (2010) Cell surface relocation of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. *J Biol Chem* 285: 15065-15075.

17. Ravindran S, Narayanan K, Eapen AS, Hao J, Ramachandran A, et al. (2008) Endoplasmic reticulum chaperone protein GRP-78 mediates endocytosis of dentin matrix protein 1. *J Biol Chem* 283: 29658-29670.
18. Lee AS (2014) Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. *Nat Rev Cancer* 14: 263-276.
19. Yao X, Liu H, Zhang X, Zhang L, Li X, et al. (2015) Cell Surface GRP78 Accelerated Breast Cancer Cell Proliferation and Migration by Activating STAT3. *PLoS One* 10: e0125634.
20. Spike BT, Kelber JA, Booker E, Kalathur M, Rodewald R, et al. (2014) CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo. *Stem Cell Reports* 2: 427-439.
21. Corrigan VM, Bodman-Smith MD, Brunst M, Cornell H, Panayi GS, et al. (2004) Inhibition of antigen-presenting cell function and stimulation of human peripheral blood mononuclear cells to express an antiinflammatory cytokine profile by the stress protein BiP: relevance to the treatment of inflammatory arthritis. *Arthritis Rheum* 50: 1164-1171.
22. Corrigan VM, Vittecoq O, Panayi GS (2009) Binding immunoglobulin protein-treated peripheral blood monocyte-derived dendritic cells are refractory to maturation and induce regulatory T-cell development. *Immunology* 128: 218-226.
23. Kayama M, Nakazawa T, Thanos A, Morizane Y, Murakami Y, et al. (2011) Heat shock protein 70 (HSP70) is critical for the photoreceptor stress response after retinal detachment via modulating anti-apoptotic Akt kinase. *Am J Pathol* 178: 1080-1091.
24. Tsutsumi YM, Horikawa YT, Kinoshita M, Tsutsumi R, Tanaka K, et al (2011) Geranylgeranylacetone induced delayed cardiac preconditioning requires caveolin-3. *FASEB J* 25: 1085-1097.
25. Hirakawa T, Rokutan K, Nikawa T, Kishi K (1996) Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. *Gastroenterology* 111: 345-357.
26. Esfandiari F, Medici V, Wong DH, Jose S, Dolatshahi M, et al (2010) Epigenetic regulation of hepatic endoplasmic reticulum stress pathways in the ethanol-fed cystathionine beta synthase-deficient mouse. *Hepatology* 51: 932-941.
27. Estève PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, et al. (2006) Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. *Genes Dev* 20: 3089-3103.
28. Zhang T, Termanis A, Özkan B, Bao XX, Culley J, et al. (2016) G9a/GLP Complex Maintains Imprinted DNA Methylation in Embryonic Stem Cells. *Cell Rep* 15: 77-85.
29. Hynes K, Menicanin D, Gronthos S, Bartold PM (2012) Clinical utility of stem cells for periodontal regeneration. *Periodontol* 2000 59: 203-227.
30. Bassir SH, Wisitrasameewong W, Raanan J, et al. (2016) Potential for Stem Cell-Based Periodontal Therapy. *J Cell Physiol* 231: 50-61.